Its turnover declined 9%, to RON414 million.
Its operating profit grew 179%, to RON291 million, mainly influenced by revenues obtained from the sale of a product portfolio to France’s Sanofi as Zentiva was acquired by investment fund Advent International.
The company’s assets grew 75%, to RON868 million from RON497 million in 2017.
Zentiva’s production facility in Bucharest makes 130 products and exports nearly 60% of its output to 24 countries, mostly throughout Europe.
After Romania, Germany is the Romanian pharmaceutical produce’s largest market.
In 2018, after nine years, France’s Sanofi discarded its generics division and sold Zentiva to Advent International.